New treatment funded for Acute Lymphocytic Leukaemia
![](https://snowdome.org.au/app/uploads/2020/04/0142_HappyGirl.jpg)
As of 1st May 2019 Inotuzumab (Besponsa) will be available on the PBS for patients with relapsed acute lymphocytic leukaemia (ALL) or refractory CD22 positive B-cell precursor ALL. The treatment costs $120,000 per course but due to funding you will only pay $40.30 or $6.50 (for concession card holders) a course.
Acute lymphocytic leukaemia occurs in approximately 300 adults and children every year with children accounting for 60% of the cases.